Pancreatic cystic lesions are increasingly being recognized on imaging studies. Among these, intraductal papillary mucinous neoplasms (IPMNs) frequently exhibit a spectrum of neoplastic transformation and follow-up is recommended according to the Sendai [1] and Fukuoka criteria [2] , with the preference being for magnetic resonance imaging (MRI) [3] . Endoscopic ultrasound (EUS) can help to verify the absence of thickened walls or mural nodules [2] . We report on a 75-year-old woman who was referred to our emergency department with nausea and chest pain. Her physical examination was unremarkable and her laboratory parameters were within the reference ranges, except for a slightly elevated lipase. Computed tomography (CT) of the abdomen revealed a cystic lesion between the body and tail of the pancreas (• " Fig. 1 ). On EUS, a connection between the cystic lesion and the main pancreatic duct (MPD) was seen (• " Fig. 2 ) and therefore a branch duct IPMN was diagnosed. MRI showed a 1.8 × 1.5-cm cyst with a connection to the MPD (• " Fig. 3 and• " Fig. 4 ). After 2 months the patient was re-examined with a contrast-enhanced EUS. The cyst showed an increased size with a persistent contrast-enhancing thickened wall Fig. 6 ) with no evidence of a mucinous epithelium. Immunohistochemistry showed positivity for synaptophysin and somatostatin receptor. The patient was referred for a surgical resection. This case adds to concerns about the current management of pancreatic cystic lesions and shows that every neoplasm of the pancreas that involves the pancreatic duct can mimic IPMN. In pancreatic cysts with worrisome features, a thorough investigation should be undertaken.
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Video 1
Magnetic resonance imaging (MRI) showing a pancreatic cyst with connection to the main pancreatic duct and thickened walls; magnetic resonance cholangiopancreatography (MRCP) suggesting a branch duct intraductal papillary mucinous neoplasm (BD-IPMN) ; contrast-enhanced transabdominal and endoscopic ultrasound (EUS) using 4.8 mL SonoVue (equates to Lumason) showing the hyperenhanced thickened wall and a fine needle biopsy of the lesion being taken.
